Dianthus Therapeutics, Inc. /DE/ Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q3 2024.
  • Dianthus Therapeutics, Inc. /DE/ Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$25.2M, a 70.5% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$67.1M, a 55.6% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Income (Loss) Attributable to Parent for 2023 was -$43.6M, a 53% decline from 2022.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Income (Loss) Attributable to Parent for 2022 was -$28.5M, a 117% decline from 2021.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Income (Loss) Attributable to Parent for 2021 was -$13.1M, a 82.5% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$67.1M -$25.2M -$10.4M -70.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$56.7M -$17.6M -$6.47M -58.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$50.2M -$13.7M -$6.66M -93.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$43.6M -$10.6M -$447K -4.42% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$43.1M -$14.8M -$6.98M -89.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$36.1M -$11.1M -$5.45M -95.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$30.7M -$7.09M -$2.21M -45.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$28.5M -$10.1M -$48.9M -126% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $20.4M -$7.78M +$9.64M +55.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $10.7M -$5.7M +$11.2M +66.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$501K -$4.88M +$12.6M +72.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$13.1M $38.7M +$56.9M Oct 1, 2021 Dec 31, 2021 8-K 2023-12-21
Q3 2021 -$70M -$17.4M +$251K +1.42% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$70.3M -$16.9M +$2.15M +11.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$72.4M -$17.5M +$2.52M +12.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$74.9M -$18.2M +$5.07M +21.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 -$80M -$17.7M +$3.31M +15.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$83.3M -$19.1M -$1.37M -7.74% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$81.9M -$20M -$5.18M -34.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$76.8M -$23.2M -$6.56M -39.3% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-03
Q3 2019 -$70.2M -$21M -$4.98M -31.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$65.2M -$17.7M -$4.05M -29.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$61.2M -$14.8M -$3.67M -32.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$57.5M -$16.7M -$8.64M -108% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 -$48.9M -$16M -$9.1M -132% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-03
Q2 2018 -$39.8M -$13.7M +$2.07M +13.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-03
Q1 2018 -$41.8M -$11.2M -$6.35M -132% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-03
Q4 2017 -$35.5M -$8.04M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-19
Q3 2017 -$6.91M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-19
Q2 2017 -$15.7M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-19
Q1 2017 -$4.81M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.